静脉性胸廓出口减压的管理与结局:向锁骨下入路的转变
单中心回顾性 review 了2007至2022年76例因静脉性胸廓出口综合征行肋骨切除的患者,平均年龄36岁,93%以肿胀起病,90%合并深静脉血栓。91%经锁骨下入路手术,83%术前或术中接受血管内干预;术后并发症14%,再干预22%,末次随访97%锁骨下静脉通畅、93%无症状。
要点
- 静脉性胸廓出口综合征患者90%合并深静脉血栓,99%术前启动抗凝。
- 91%经锁骨下入路行肋骨切除,83%术前或术中接受血管内干预。
- 末次随访97%锁骨下静脉通畅、93%患者无症状,围术期无死亡或神经损伤。
核心结论
- 过去十年本中心对孤立性静脉性胸廓出口综合征已转为锁骨下入路,围术期并发症低且通畅率良好。
- 作者认为这些结果支持采用锁骨下入路联合辅助血管内技术作为静脉性胸廓出口综合征安全有效的治疗。
研究设计与样本
- 单中心回顾性 review,纳入2007至2022年在本机构因静脉性胸廓出口综合征接受肋骨切除的全部患者,共76例。
- 回顾人口学、手术细节及围术期与长期结局。
主要发现
- 平均年龄36岁;肿胀为最常见症状(93%),其次为疼痛(6.6%)。
- 90%患者合并深静脉血栓,其中99%术前开始抗凝。
- 91%经锁骨下入路行肋骨切除,2%经锁骨旁入路(因神经源性成分),7%经腋入路。
- 83%患者在肋骨切除术前或术中接受血管内干预,最常见为导管定向溶栓(87%)、血管成形术(71%)和流变学血栓清除术(57%)。
- 血管内干预至肋骨切除的中位时间为14天,25%在同一次住院期间完成;术后中位住院3天(2-5天);围术期无死亡或神经损伤;14%出现术后并发症,以出血并发症(12%)最常见;初次血管内干预与肋骨切除间隔超过30天与出血并发症风险降低无关;22%接受再干预,最常见为血管成形术(21%);末次随访97%锁骨下静脉通畅、93%患者无症状。
临床怎么用
- 作者认为可支持采用锁骨下入路联合辅助血管内技术治疗静脉性胸廓出口综合征。
- 术后1个月行体格检查、6个月行 duplex 超声随访,或出现新发或复发症状时就诊。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Venous thoracic outlet syndrome (vTOS) is caused by compression of the subclavian vein at the costoclavicular space, which may lead to vein thrombosis. Current treatment includes thoracic outlet decompression with or without venolysis. However, given its relatively low prevalence, the existing literature is limited. Here, we report our single-institution experience in the treatment of vTOS. METHODS: We performed a retrospective review of all patients who underwent rib resection for vTOS at our institution from 2007 to 2022. Demographic, procedural details, and perioperative and long-term outcomes were reviewed. RESULTS: A total of 76 patients were identified. The mean age was 36 years. Swelling was the most common symptom (93%), followed by pain (6.6%). Ninety percent of patients had associated deep vein thrombosis, with 99% of these patients starting anticoagulation preoperatively. A total of 91% of patients underwent rib resection via the infraclavicular approach, 2% via the paraclavicular approach (due to a neurogenic component), and 7% via the transaxillary approach. Eighty-three percent of patients had endovascular intervention before or at the time of the rib resection, with catheter-directed thrombolysis (87%), followed by angioplasty (71%) and rheolytic thrombectomy (57%) being the most common interventions. The median time from endovascular intervention to rib resection was 14 days, with 25% at the same admission. The median postoperative stay was 3 days (2-5 days). There was no perioperative mortality or nerve injury. Fourteen percent of patients had postoperative complications, with bleeding complications (12%) being the most common. Waiting more than 30 days between initial endovascular intervention and rib resection was not associated with decreased risk of bleeding complications. Patients were seen postoperatively at 1-month (physical examination) and 6-month (duplex) intervals or for any new or recurrent symptoms. Twenty-two percent of our overall patient population underwent reintervention, most commonly angioplasty (21%). At last follow-up, 97% of subclavian veins were patent, and 93% of patients were symptom free. CONCLUSIONS: Over the last decade, we have transitioned to an infraclavicular approach for isolated vTOS, with low perioperative morbidity and good patency rates. These results support the adoption of the infraclavicular approach with adjunct endovascular techniques as a safe and efficacious treatment of vTOS.
引用
- Mota L, Tomeo JN, Yadavalli SD, et al. Management and outcomes of venous thoracic outlet decompression: A transition to the infraclavicular approach. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 39103050. doi:10.1016/j.jvsv.2024.101959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。